Epigenomics Q1 Revenues Rise 15 Percent as it Awaits FDA, CFDA Decisions | GenomeWeb

NEW YORK (GenomeWeb) – Epigenomics today reported a 15 percent year-over-year increase in its first quarter revenues as product revenues were up 32 percent.

The German-American molecular diagnostics company said that for the three months ended March 31, revenues rose to €407,000 ($559,000) from €355,000. Product revenues increased to €215,000 from €163,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.